Alzheimer's Prevention Initiative
We are launching a new era of Alzheimer's prevention research.
Championed and led by Banner Alzheimer's Institute (BAI), the Alzheimer's Prevention Initiative (API) is an international collaborative formed to launch a new era of Alzheimer's prevention research by evaluating the most promising therapies in cognitively normal people who, based on their age and genetic background, are at the highest imminent risk of developing Alzheimer's disease symptoms.
The API, which includes scientists, physicians and industry and regulatory agency representatives, is focused on prevention and treatment trials, biomarker studies and registries. These efforts are conducted in collaboration with the Arizona Alzheimer's Consortium and partners around the world. The ultimate goal is to someday postpone, reduce the risk of, or prevent the clinical onset of Alzheimer's.
Alzheimer's Prevention Initiative Autosomal Dominant
Alzheimer's Disease Treatment Trial
In collaboration with the National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), University of Antioquia's Grupo de Neurosciencias in Medellin, Colombia and Genentech, are conducting the first‐ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer's disease because of their genetic history.
This groundbreaking study - the first to investigate whether an anti‐amyloid treatment can stave off the disease-will help launch a new era of prevention research in the urgent fight against Alzheimer's.
The $100 million trial is the cornerstone of the API. It is studying an experimental anti‐amyloid antibody treatment called crenezumab in approximately 300 people from an extraordinarily large extended family in Colombia, who share a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45.
The trial is designed to determine whether the drug can reduce participants' chances of developing the disease's disabling and irreversible symptoms, preserve memory and thinking abilities, and slow the progression of Alzheimer's biomarkers.
Alzheimer's Prevention Initiative APOE4 Treatment
In July 2014, BAI announced a partnership with Novartis for a pioneering medical trial to determine whether two investigational anti-amyloid drugs can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages. The study is partially funded by a $33.2 million grant commitment from the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services, and more than $15 million in philanthropic and in-kind contributions by Banner Alzheimer's Foundation.
The two drugs include an active immunotherapy aimed at triggering the body's immune system to produce antibodies that attack different forms of the amyloid protein, which many researchers have suggested plays a critical role in the development of Alzheimer's. The second drug, an oral medication, is a BACE (beta-secretase1) inhibitor, designed to prevent the production of different forms of the amyloid protein.
Trial participants will receive the active immunotherapy, the oral medication or a placebo. The study will involve about 60 sites in Europe and North America. It is scheduled to begin in the second half of 2015 and last five years.
If you are interested in participating in this or any other future prevention trials, join the Alzheimer's Prevention Registry.
Alzheimer's Prevention Registry
The Alzheimer's Prevention Registry (Registry) is a community of people interested in making an impact on Alzheimer's research to help stop the disease. Members receive regular updates on the latest scientific advances and news, and are connected to potential prevention research studies taking place in their communities. The Registry supports enrollment into a variety of Alzheimer's prevention studies across the country.
Learn more about the Registry at www.endALZnow.org. Members are under no obligation to participate in prevention studies.